Patents Examined by Yevgeny Valenrod
  • Patent number: 12012378
    Abstract: The present invention relates to a process for preparing the 2-bromoglutaric acid diester of formula (I) below: comprising the formation of the 2-hydroxyglutaric acid diester of formula (II) by reaction of butyrolactone acid of formula (BA) with the alcohol of formula ROH, in the presence of an acid such as sulfuric acid; and bromination of the 2-hydroxyglutaric acid diester of formula (II), by sparging with gaseous hydrobromic acid. The present invention also relates to a 2-bromoglutaric acid diester of formula (I), having a degree of purity determined by HPLC analysis of greater than or equal to 90%.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: June 18, 2024
    Assignee: GUERBET
    Inventors: Jean-Michel Paratian, Martine Cerf
  • Patent number: 12005118
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: June 11, 2024
    Assignee: Axsome Therapeutics, Inc.
    Inventor: Herriot Tabuteau
  • Patent number: 12005045
    Abstract: The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.
    Type: Grant
    Filed: November 22, 2023
    Date of Patent: June 11, 2024
    Assignee: AURIGENE ONCOLOGY LIMITED
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • Patent number: 11999687
    Abstract: Efficient methods of producing L-threonic acid from L-xylonic acid are disclosed.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: June 4, 2024
    Assignee: DFI USA, LLC
    Inventors: Jonathan Stapley, David Genders
  • Patent number: 11999690
    Abstract: A method for preparing a partially fluorinated ester comprising acyl and alkoxy groups wherein the acyl group comprises a branched or linear fluorine containing C3-C8 group with one of the structures: (Formulae (I), (II)) wherein X and Y are independently selected from: —H, —CH3, —F, —Cl, —CH2F, —CF3—OCF3, —OCH2CF3, OCH2CF2CHF2 and —CH2CF3 (wherein both X and Y cannot be H) comprising reacting an unsaturated halocarbon: (Formula (III)) wherein A and B are independently selected from the group comprising —H, —CH3, —F, —Cl, —CH2F, —CF3, —OCF3, —OCH2CF3, OCH2CF2CHF2 and —CH2CF3 (wherein both A and B cannot be H) with carbon monoxide and an alcohol, in the presence of a catalyst methods.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: June 4, 2024
    Assignee: Mexichem Fluor S.A. de C.V.
    Inventors: Andrew P. Sharratt, John Charles McCarthy
  • Patent number: 11999757
    Abstract: Disclosed herein are methods for the preparation of boronate derivatives in the synthesis of antimicrobial compounds and uses thereof. Disclosed herein includes method of making a compound of Formula (B) by reducing the ketone group of the keto-ester compound of Formula (A), and the reduction can be performed using a Ruthenium based catalyst system or using an alcohol dehydrogenase bioreduction system.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: June 4, 2024
    Assignee: MELINTA SUBSIDIARY CORP.
    Inventors: Serge Henri Boyer, Scott J. Hecker, Gerardus K. M. Verzijl, Petrus J. Hermsen
  • Patent number: 11987541
    Abstract: In the embodiments, an aqueous hydrochloric acid solution instead of hydrogen chloride gas and solid triphosgene instead of phosgene gas may be used in the process of preparing a diisocyanate from a diamine through a diamine hydrochloride. In addition, the embodiments provide processes for preparing a diisocyanate composition and an optical lens, which are excellent in yield and quality with mitigated environmental problems by controlling the size of the diamine hydrochloride composition, the b* value according to the CIE color coordinate of the diamine hydrochloride composition, or the content of water in the diamine hydrochloride composition within a specific range.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: May 21, 2024
    Assignees: SK PUCORE CO., LTD., WOORI FINE CHEM CO., LTD.
    Inventors: Jaeyoung Pai, Jeongmoo Kim, Hyuk Hee Han, Jung Hwan Myung
  • Patent number: 11986443
    Abstract: This disclosure relates to a method of reducing a fat deposit comprising injecting an alcohol-containing pharmaceutical composition into the fat deposit. The method may be effective in improving the appearance of or reducing the weight or volume of the fat deposit.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: May 21, 2024
    Assignee: Polithera, Inc.
    Inventors: Adam M. Rotunda, Vince Afsahi
  • Patent number: 11986477
    Abstract: The present disclosure relates to the combination of IN10018 and an epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of tumors.
    Type: Grant
    Filed: November 6, 2023
    Date of Patent: May 21, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Baoyuan Zhang, Xuebin Liu, Jiaming Gao, Ping Zhang, Ran Pang, Zaiqi Wang
  • Patent number: 11980862
    Abstract: A hybrid vertical plug flow reactor is comprised of a bottom inlet and a top outlet having vertical tubular member disposed there between, wherein the bottom inlet has separate gas reactant inlet and separate liquid reactant inlet whereby the gas reactant is mixed with the liquid reactant and the outlet has an extraction port, the extraction port extending sufficiently to withdraw the liquid product from the reactor and maintain a gaseous head space within the tubular member of the reactor. The hybrid vertical bubble plug flow reactor is useful to react a gas reactant and liquid reactant that are reacted at a molar ratio of gas reactant/liquid reactant that is in excess of a stoichiometric requirement of gas reactant so that the gas reactant forms bubbles and the reactants react in the presence of a catalyst to form a reaction product.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: May 14, 2024
    Assignee: Novomer, Inc.
    Inventors: Branden Cole, Jeff Uhrig
  • Patent number: 11981624
    Abstract: The present disclosure encompasses crystalline polymorphs of Rigosertib Sodium, processes for preparation thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: May 14, 2024
    Inventors: Pavel Kolesa, Roman Gabriel, Alexandr Jegorov
  • Patent number: 11980592
    Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at least a first selected terpene. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, or Huntington's disease.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: May 14, 2024
    Assignee: GBS Global Biopharma, Inc.
    Inventors: Andrea Small-Howard, Helen Turner
  • Patent number: 11976038
    Abstract: The present disclosure provides a preparation method of resveratrol nervonic acid ester, comprising the following steps of: step 1: weighing resveratrol, a nervonic acid and thiocarbonyldiimidazole according to a molar ratio of 1:1:0.8 to 1:7:11.2 in a reactor; step 2: adding a certain amount of solvent into the reactor to completely dissolve the reactants; and step 3: stirring for reaction at room temperature for 30 min to 180 min. The preparation method is safe, efficient and clean, and enables synthesis of the resveratrol nervonic acid ester with high conversion rate, high purity and high yield.
    Type: Grant
    Filed: December 28, 2023
    Date of Patent: May 7, 2024
    Assignee: INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, CHINESE ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Qiang Wang, Qin Guo, Tian Li, Xiaoning Hu, Manzhu Liang, Yang Qu, Zhenyuan Li
  • Patent number: 11976037
    Abstract: This invention concerns a process for the production of vinyl esters of carboxylic acids with 3 to 20 carbon atoms, via vinylation in the presence of palladium (Pd) catalyst in combination with copper (Cu) as co-catalyst stabilized by organic salts in the presence of ethylene and air or oxygen.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: May 7, 2024
    Assignee: HEXION INC.
    Inventors: Fabrizio Marras, Leo Sliedregt, Alexander Kraynov
  • Patent number: 11970438
    Abstract: There is provided a compound having a structure represented by the following Formula (1), in Formula (1), R1 and R2 each independently represent a phenyl group having a substituent or an unsubstituted phenyl group, R3 and R4 each independently represent a C2-C12 alkyl group having a substituent or an unsubstituted C2-C12 alkyl group, a cyano group, a trifluoromethyl group, or a halogen atom, R5 and R6 each independently represent a hydrogen atom or an alkyl group, R7 represents a phenyl group having a substituent, an unsubstituted phenyl group, or a heteroaromatic group having a specific structure, and X? represents an anion, and in a case where at least one anionic substituent is included in a molecule, X? may not be present.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: April 30, 2024
    Assignee: Canon Kabushiki Kaisha
    Inventors: Ai Hayakawa, Koromo Shirota, Taichi Shintou, Tsuyoshi Santo
  • Patent number: 11969407
    Abstract: The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: April 30, 2024
    Assignee: TRANSCEND THERAPEUTICS, INC.
    Inventors: Blake Mandell, Martin Stogniew, Jennifer Louise Schmidt, Markus Seelig
  • Patent number: 11957661
    Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: April 16, 2024
    Assignee: Incyte Corporation
    Inventors: Paul Smith, Kurt Andrew Brown, Michael D. Howell, Fiona Kuo, James Lee, Leandro Luiz Dos Santos, Beth Rumberger
  • Patent number: 11957648
    Abstract: The present invention provides a novel method of initiating or escalating dofetilide dosage with the goal of maximizing patient safety while shortening the time period required for electrocardiographic monitoring from three days to one day.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: April 16, 2024
    Assignee: HYLORIS DEVELOPMENTS S.A.
    Inventor: John Somberg
  • Patent number: 11958800
    Abstract: The invention relates to a method for preparation of (meth)acrylic acid esters from (meth)acrylic acid anhydrides. Wherein the method for preparation of the (meth)acrylic acid ester, comprises at least step (a) as follows: (a) reacting a (meth)acrylic acid anhydride of Formula (I): wherein R1 is a hydrogen atom or a methyl group; with a substrate in the presence of a first catalyst to form a product mixture comprising the (meth)acrylic acid ester; and wherein: the substrate is selected from the group consisting of: primary alcohols; secondary alcohols; tertiary alcohols; and phenols; and the first catalyst comprises a salt of magnesium or of a rare earth element.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: April 16, 2024
    Assignee: Evonik Operations GmbH
    Inventors: Marcel Treskow, Silvia Beyer, Thorben Schutz, Steffen Krill
  • Patent number: 11958798
    Abstract: The present invention relates to a process for the preparation of iloprost of formula I through new intermediates, isolation of iloprost of formula I in solid form, as well as preparation of the 16(S)-iloprost and 16(R)-iloprost isomers of formulae (S)-I and (R)-I and isolation of iloprost of formula I and 16(S)-iloprost of formula (S)-I in solid, crystalline form.
    Type: Grant
    Filed: October 25, 2022
    Date of Patent: April 16, 2024
    Assignee: EUROAPI HUNGARY LIMITED LIABILITY COMPANY
    Inventors: Imre Rozsumberszki, Zsuzsanna Kardos, Irén Hortobágyi, Tibor Szabó, Csaba Váradi, Tamás Bán